Oncopeptides

• Placement of 12,295,000 shares, c. 22.2% of Oncopeptides’ outstanding share capital, at a price of SEK 115 per share, representing a discount of 10.2% to the last closing price
• The accelerated bookbuilding process generated strong demand from long-only Life Science specialist investors as well as momentum players from both Europe and the United States
• Gross proceeds amount to SEK 1,414 million / USD 144 million and are expected to be used to fund the commercial launch and initial ramp-up of meflufen, including the commercial scale-up to execute a market launch in the United States, expansion of ongoing clinical development, and general corporate purposes
  Kempen & Co has been supporting Oncopeptides for an extended period of time and the Company is one of Kempen & Co’s Life Sciences Research team’s top picks for 2020
• This transaction represents the largest accelerated bookbuild offering for a development stage European Life Sciences company in 2020,  despite the onset of the COVID-19 crisis
• Kempen & Co played an instrumental role bringing high quality specialist investors into the transaction, sourced from its network spanning both Europe and the United States
  Over the past 18 months, this transaction marks Kempen & Co’s fourth in the Nordics region where it retains a strong ambition to work with innovative companies

Oncopeptides is a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The Company is focusing on the development of the lead product candidate melflufen, a first-in-class anti-cancer peptide-drug conjugate that rapidly delivers an alkylating payload into tumor cells. Melflufen is in development as a new treatment for the hematological cancer multiple myeloma and is currently being evaluated in multiple clinical studies including the pivotal phase 2 HORIZON study and the ongoing phase 3 OCEAN study. Oncopeptides’ headquarters is in Stockholm, Sweden with U.S. headquarters in Boston, Mass. The Company is listed in the Mid Cap segment on Nasdaq Stockholm with the ticker ONCO.

Over the past year, Kempen & Co has successfully completed a large number of transactions in its Life Sciences & Healthcare franchise. Recent transactions include: Co-Manager in the USD 154 million Global Offering of DBV Therapeutics, Joint Global Coordinator and Joint Bookrunner in the €19.0 million capital increase by Sequana Medical, Lead Manager in the USD 557 million Global offering by argenx, Co-Manager in the USD 79.2 million US public offering by Merus, Co-Manager in the USD 57.5 million capital increase by ProQR, Co-Manager in the USD 150 million NASDAQ Initial Public Offering of BioNTech, Sole Bookrunner in the €9.0 million capital increase by MDxHealth, Co-Manager in the USD 20 million global offering of Celyad, Co-Manager in the USD 582 million NASDAQ Initial Public Offering of Genmab, Joint Bookrunner in the €116 million secondary sale of Fagron shares by Waterland and Baltisse, Joint Bookrunner in the €48.7 million rights issue by Transgene, Joint Bookrunner in the SEK 727 million capital increase by Oncopeptides, Co-Manager in the USD 84 million NASDAQ Initial Public Offering of HOOKIPA Pharma